BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
Daniel B. Costa(Beth Israel Deaconess Medical Center), Susumu Kobayashi(Beth Israel Deaconess Medical Center)
Cited by 490
Related Papers
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
|JAMA Oncology|2018|689
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
|Journal of Clinical Oncology|2011|590
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
|Cancer Cell|2006|451
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2011|379